22 mg) of buprenorphine to the combination product, dose adjustments may be necessary especially in the later phase of the treatment. We recommend that a transfer from Subutex to Suboxone should be carefully discussed and planned in advance with the patients and after the transfer adverse events should be regularly monitored. With regard of buprenorphine IV abuse, the combination product seems to have a less abuse potential than buprenorphine alone."/>
Skip to main content

Table 4 Summary of adverse events by type and study period.

From: A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)

SOC Preferred Term Adverse Events 4-Weeks (n) (%)a Adverse Events Follow up (n) (%)b
Patients 64   60  
Patients who Experienced Adverse Events 32 50.0 16 26.6
Palpitations 4 6.3 0 0
Abdominal Pain Upper 3 4.7 3 4.9
Diarrhea 4 6.3 2 3.3
Dyspepsia 7 10.9 0 0
Gastrointestinal Pain 10 15.6 3 4.9
Nausea 13 20.3 8 13.1
Vomiting 7 10.9 2 3.3
Asthenia 2 3.1 2 3.3
Fatigue 8 12.5 9 14.8
Pain 4 6.3 0 0
Headache 8 12.5 6 9.8
Tremor 4 6.3 1 1.6
Insomnia 4 6.3 2 3.3
Irritability 1 1.6 3 4.9
Hyperhidrosis 8 12.5 3 4.9
Rash 2 3.1 2 3.3
  1. a: Percentage based on all 64 patients. b: Percentage based on the 60 patients who were treated with Suboxone during the follow-up period.